CureVac N.V. (CVAC) saw downtrend of -1.84% in the recent, registering $55.42 being its most recent bid. The distance of current price level is -34.80% lower than the highest price of $85.00 marked by the stock while trading over the past 52-weeks, whereas it is 53.31% higher than the lowest price of $36.15 the company dropped to over past 52-weeks. The latest news story on CVAC appeared in Investor’s Business Daily under the title “Covid Report: Regeneron, Moderna, CureVac Up As Possible Coronavirus Cures Advance” on Sep-30-20.

Squeezing the time span to 30 day period shows us the stock currently buoying -5.26% below one month high and is +28.88% above of the lowest during that time.

Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. During the reported three-month period, company’s sales were $3.44 billion while analysts on average were estimating the same to be $3.71 million.

3 analysts covering the stock at Wall Street were agreed upon that EPS consensus.

Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). Institutions currently hold 176.47 million of CVAC’s outstanding shares.

As on Aug 30, 2020, John Hancock Var Ins Tr-Health Sciences Tr was the top most holder in CureVac N.V. (NASDAQ:CVAC) with an ownership of 11077.0 shares of the company or 0.01% of the stake worth $0.61 million.

Investors are for sure keenly observing the recommendations of analysts at Wall Street about the CureVac N.V. And review of current evaluations agreed by the analysts discloses a Buy rating for CVAC. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock. Lower value of between 1 and 2 implies a Buy recommendation whereas the value in the range of above 4 suggests Hold while below 1 recommends the investors to Sell the stock. Currently, the stock has been recommended as Moderate Buy by 5 of the Wall Street analysts.